RadioMedix
RadioMedix is a Houston-based clinical-stage biotechnology company developing targeted radiopharmaceuticals (Pb-212, Ga-68, Ac-225) for cancer diagnosis and therapy, with integrated cGMP manufacturing at its SPICA Center and a $100M+ licensing deal with Sanofi for its lead AlphaMedix asset.
- Company typePrivate
- Founded2006
- HeadquartersHouston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RadioMedix does
RadioMedix is a clinical-stage biotechnology company founded in 2006 and headquartered in Houston, Texas, that develops targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Its core technology platform centers on alpha- and beta-emitting isotopes — including Lead-212 (Pb-212), Actinium-225 (Ac-225), Lutetium-177 (Lu-177), Lead-203 (Pb-203), and Gallium-68 (Ga-68) — engineered into both PET imaging diagnostics and targeted alpha therapy (TAT) agents. The flagship therapeutic asset, AlphaMedix (212Pb-DOTAMTATE), is a Pb-212-labeled somatostatin analogue for neuroendocrine tumors that received FDA Breakthrough Therapy Designation in February 2024 and demonstrated a 62.5% objective response rate in Phase 2. The diagnostic portfolio includes FDA-approved Ga-68 PSMA-11 (Gozetotide) for prostate cancer imaging, plus investigational 68Ga-RMX-VH and 203Pb-RMX-VH-PIB companion diagnostics targeting LDLR in glioblastoma multiforme and pancreatic ductal adenocarcinoma. The proprietary RAHA-100 bench-top Pb-212 generator, launched in June 2025, enables on-demand isotope production for both internal pipeline use and external distribution.
The company operates a vertically integrated model combining early-stage R&D, clinical development, and cGMP commercial-scale manufacturing at the 27,500 sq. ft. SPICA Center facility in Humble, Texas, which houses six aseptic clean rooms and full 21 CFR 211 compliance. Revenue is generated through three principal streams: (1) licensing and milestone/royalty payments from pharmaceutical partners — most notably the September 2024 exclusive global licensing agreement with Sanofi for AlphaMedix (€100M upfront plus up to €220M in sales milestones and tiered royalties); (2) CDMO/contract manufacturing services for biopharma and academic clients at the SPICA Center; and (3) direct commercialization of FDA-approved diagnostic products such as Ga-68 PSMA-11. To secure upstream supply, RadioMedix has executed dual five-year Thorium-228 supply agreements with Thor Medical ASA and Van Overeem Nuclear B.V. (announced December 2025). The company is founder-led by Dr. Ebrahim Delpassand (former MD Anderson chief of clinical nuclear medicine), with a team of approximately 40 employees, and has previously divested non-core assets such as the 225Ac-PSMA I&T program to Fusion Pharmaceuticals.
RadioMedix firmographics
Firmographics- Name
- RadioMedix
- Legal name
- RadioMedix, Inc.
- Website
- https://radiomedix.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RadioMedix is a Houston-based clinical-stage biotechnology company developing targeted radiopharmaceuticals (Pb-212, Ga-68, Ac-225) for cancer diagnosis and therapy, with integrated cGMP manufacturing at its SPICA Center and a $100M+ licensing deal with Sanofi for its lead AlphaMedix asset.
- Ownership category
- akta.pro rank
RadioMedix industry classification
Industry- Product category
- Radiopharmaceuticals / Targeted Radiotherapy
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)
Keywords
Where RadioMedix is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
RadioMedix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales, Operations
Revenue model
- Licensing and Milestone Payments: RadioMedix licenses its proprietary technologies and drug candidates to major pharmaceutical partners. Received €100 million upfront payment from Sanofi for AlphaMedix licensing, plus up to €220 million in sales milestones and tiered royalties. This represents the primary revenue stream for the company.
- CDMO/Contract Manufacturing Services: RadioMedix provides contract manufacturing and development services for radiopharmaceuticals to academic and industrial partners through its SPICA Center facility. Services include radiochemistry solutions, analytical method development, process validation, and GMP manufacturing.
- Product Sales: Direct commercialization of FDA-approved diagnostic radiopharmaceuticals including Ga-68 PSMA-11 (Gallium Ga 68 Gozetotide Injection) for prostate cancer imaging.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
RadioMedix product offering
Product offeringCore offering
RadioMedix develops and commercializes targeted radiopharmaceuticals for oncology, including targeted alpha therapy (TAT) agents such as AlphaMedix (212Pb-DOTAMTATE) for neuroendocrine tumors, the proprietary RAHA-100 bench top 212Pb generator for on-demand isotope production, and PET diagnostic imaging agents such as FDA-approved Ga-68 PSMA-11 for prostate cancer. The company also provides CDMO/contract manufacturing services for radiopharmaceuticals through its cGMP SPICA Center facility.
Product overview
RadioMedix is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer diagnosis and therapy. The company operates from a unified product portfolio centered on alpha-emitter based therapies (Targeted Alpha Therapy) and diagnostic imaging agents. The core therapeutic product is AlphaMedix (212Pb-DOTAMTATE), a lead-212 labeled somatostatin analogue for neuroendocrine tumors. Supporting the pipeline is RAHA-100, a proprietary bench top 212Pb generator enabling on-demand isotope production. The diagnostic portfolio includes Ga-68 PSMA-11 (FDA-approved), 68Ga-RMX-VH, and 203Pb-RMX-VH-PIB for various cancer imaging applications. Manufacturing capabilities are anchored by the SPICA Center, a 27,500 sq. ft. cGMP facility supporting both clinical and commercial-scale production. The company also licensed DetectNet to Curium and previously sold its 225Ac-PSMA I&T program to Fusion Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Brands
- RAHA-100: Proprietary bench top generator technology designed to streamline the production of on-demand supply of Lead-212 (212Pb) isotope for research and clinical development of targeted Alpha Therapy radiopharmaceuticals.
- AlphaMedix
Products and services
- AlphaMedix (212Pb-DOTAMTATE) A lead-212 (212Pb) labeled somatostatin analogue targeted alpha therapy (TAT) agent for the treatment of metastatic or inoperable somatostatin-expressing neuroendocrine tumors. Uses 212Pb as an in vivo generator of alpha particles for precise tumor cell destruction. Demonstrated 62.5% objective response rate in Phase 2 trials.
- RAHA-100 (212Pb Generator) A proprietary bench top generator technology for streamlined on-demand production of Lead-212 (212Pb) isotope for targeted alpha therapy research and clinical development. Features fully automated synthesis, multiple high-activity modular columns, downstream purification steps, and production yield greater than 65% from elution to formulation.
- Ga-68 PSMA-11 (Gozetotide) An FDA-approved radioactive diagnostic agent for PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Indicated for patients with suspected metastasis who are candidates for initial definitive therapy and those with suspected recurrence based on elevated PSA. Supplied as clear, colorless solution at 18.5 MBq/mL to 185 MBq/mL.
- 68Ga-RMX-VH A PET imaging agent targeting the Low-Density Lipoprotein Receptor (LDLR) for diagnostic imaging of Glioblastoma Multiforme (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC). Serves as companion diagnostic for future targeted alpha therapy.
- 203Pb-RMX-VH-PIB A diagnostic imaging agent targeting LDLR for PET imaging of Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma. Demonstrated significant tumor accumulation and ability to cross the blood-brain barrier in preclinical studies. Serves as companion diagnostic for future targeted alpha therapy.
- SPICA Center Contract Manufacturing (CDMO) Services Contract Development and Manufacturing Organization (CDMO) services for radiopharmaceuticals at the SPICA Center facility, including radiochemistry solutions, analytical method development, process validation, and GMP manufacturing from clinical to commercial scale. Offered to academic and industrial partners.
Quantifiable outcome
- AlphaMedix demonstrated 62.5% objective response rate (ORR) in Phase 2 trials for neuroendocrine tumors, more than twice the current standard of care
- +2 more outcomes
Companies that use RadioMedix
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
RadioMedix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
RadioMedix partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, minor and core/flagship.
- Van Overeem Nuclear B.V.coreFive-year agreement for supply of Thorium-228 (228Th). Expands RadioMedix's upstream isotope supply network to ensure reliable 212Pb production for targeted alpha therapy development and manufacturing.
- Thor Medical ASAcoreFive-year supply agreement for Thorium-228 (Th-228) starting in 2026. Thor Medical supplies the precursor for RadioMedix's production of Lead-212 (Pb-212) to support their therapeutic pipeline and RAHA-100 generator platform.
- Vect-HoruscoreCo-development and licensing agreement for theranostic agents including 68Ga-RMX-VH and 203Pb-RMX-VH-PIB for glioblastoma multiforme and pancreatic ductal adenocarcinoma. Vect-Horus provides molecular vector expertise for targeted delivery; RadioMedix handles radiopharmaceutical development and manufacturing.
- Curium PharmaminorLicensed DetectNet diagnostic imaging asset to Curium for distribution. RadioMedix retains development capabilities while Curium handles commercial distribution.
- Sanoficore/flagshipExclusive licensing agreement for AlphaMedix (212Pb-DOTAMTATE) targeting rare neuroendocrine tumors. RadioMedix and Orano Med received €100 million upfront payment and up to €220 million in sales milestones plus tiered royalties. Sanofi responsible for global commercialization while Orano Med handles manufacturing.
- Fusion Pharmaceuticals Inc.minorAcquisition of RadioMedix's 225Ac-PSMA I&T program, a targeted alpha therapy for metastatic castration resistant prostate cancer. Asset sale transaction.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
RadioMedix competitors and assessment
Company assessmentDirect peers
- Orano Med: Direct co-developer of AlphaMedix (212Pb-DOTAMTATE) and the lead producer of Pb-212 for targeted alpha therapy. RadioMedix and Orano Med jointly developed AlphaMedix and share the Sanofi licensing economics, making them the most directly comparable peer in the Pb-212 space.
- Lantheus Holdings: Radiopharmaceutical company specializing in diagnostic imaging agents including PYLARIFY (18F-DCFPyL PSMA PET tracer), directly comparable to RadioMedix's Ga-68 PSMA-11 diagnostic and broader nuclear medicine imaging portfolio.
- Telix Pharmaceuticals: Commercial-stage radiopharma company with Illuccix (Ga-68 PSMA-11 PET tracer) directly competing with RadioMedix's FDA-approved Gozetotide in prostate cancer imaging, plus an expanding therapeutic pipeline in targeted radiation.
- Curium Pharma: Global radiopharmaceutical company that licensed RadioMedix's DetectNet diagnostic imaging asset. Direct peer in nuclear medicine diagnostics distribution and a commercial partner, with overlapping product portfolios in PET imaging agents.
- Fusion Pharmaceuticals: Targeted alpha therapy developer that acquired RadioMedix's 225Ac-PSMA I&T program in 2023 and was subsequently acquired by AstraZeneca. Comparable as an alpha-emitter platform company with actinium-225-based programs targeting similar oncology indications.
- ITM Isotope Technologies Munich: Radiopharmaceutical platform company producing medical radioisotopes (including Lu-177) and developing targeted radiopharmaceutical therapies. Comparable as a vertically integrated isotope producer and radiopharma developer serving similar customer segments.
- Point Biopharma: Radioligand therapy company developing 177Lu-based PSMA and somatostatin therapies, acquired by Eli Lilly. Directly comparable to RadioMedix's AlphaMedix franchise in the targeted radionuclide therapy space for prostate and neuroendocrine tumors.
Broad incumbents
- Novartis: Established radioligand therapy leader with Lutathera (177Lu-DOTATATE for NETs) and Pluvicto (177Lu-PSMA-617 for prostate cancer). Competes head-to-head with AlphaMedix in neuroendocrine tumors and with RadioMedix's PSMA diagnostic franchise; broadly incumbent across the radiopharmaceutical value chain.
- Bayer (Radiopharmaceuticals): Broad incumbent with Xofigo (223Ra, alpha emitter for prostate cancer bone metastases) and an expanding radioligand therapy pipeline via Algeta legacy and Noria/Pepaxto acquisitions; competes with RadioMedix in the alpha-emitter therapy space.
- Bracco Imaging: Global diagnostic imaging company with a portfolio of contrast agents and nuclear medicine products. Broad incumbent serving overlapping healthcare provider customers with diagnostic imaging solutions, though not directly specializing in radiopharmaceuticals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
RadioMedix social profiles
Digital presenceRadioMedix compliance and trust
Trust signalCompliance3 records
RadioMedix financial estimates
Financial estimateRevenue estimate
Valuation estimate
RadioMedix leadership team
Management profileNumber of profiles
Profiles7 records
RadioMedix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RadioMedix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RadioMedix
What does RadioMedix do?
RadioMedix develops and commercializes targeted radiopharmaceuticals for oncology, including targeted alpha therapy (TAT) agents such as AlphaMedix (212Pb-DOTAMTATE) for neuroendocrine tumors, the proprietary RAHA-100 bench top 212Pb generator for on-demand isotope production, and PET diagnostic imaging agents such as FDA-approved Ga-68 PSMA-11 for prostate cancer. The company also provides CDMO/contract manufacturing services for radiopharmaceuticals through its cGMP SPICA Center facility.
Is RadioMedix a public or private company?
RadioMedix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RadioMedix founded?
RadioMedix was founded in 2006. It employs 11 to 50 people.
Where is RadioMedix based?
RadioMedix is headquartered in Houston, United States, in the North America region.
How does RadioMedix make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are CDMO/Contract Manufacturing Services and product Sales.
Who are RadioMedix's main competitors?
Direct peers on record are Orano Med, Lantheus Holdings, Telix Pharmaceuticals, Curium Pharma, Fusion Pharmaceuticals, ITM Isotope Technologies Munich and Point Biopharma. Broad incumbents are Novartis, Bayer (Radiopharmaceuticals) and Bracco Imaging.
Does RadioMedix have an API?
No public API is recorded for RadioMedix.
What industry is RadioMedix in?
RadioMedix's product category is Radiopharmaceuticals / Targeted Radiotherapy. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.